Published in Cardiovascular Business Week, October 26th, 2004
The study is an open-label, cross-over evaluation of two controlled release formulations of RSD1235 in comparison to an immediate release formulation. The study will enable Cardiome to evaluate and select which formulation to move forward into further clinical trials.
A controlled release oral formulation of RSD1235 is being developed as a chronic treatment for atrial fibrillation (AF). Oral RSD1235 is expected to prevent or slow the recurrence of AF, and is designed to be used as a follow-on therapy...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week